Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCMG Regimen for Relapsed/Refractory AML
NCT06741722Phase 2Recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML), sponsored by The Fifth Medical Center of the PLA General Hospital. Started Oct 2024; status: recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06741722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741722.